Skip to main content

Table 4 Characteristics of patients with stage II pure mucinous carcinoma of the breast

From: Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

  

Endocrine therapy

P

  

With chemotherapy (n = 30)

Without chemotherapy (n = 15)

 

Age, years

  

0.001

 

mean (SD)

43.43 (6.17)

61.16 (16.89)

 
 

median

44.68

64.20

 
 

range

31.0, 57.0

28.0, 84.0

 

Tumor size, cm

  

0.772

 

mean (SD)

3.60 (2.89)

3.34 (2.43)

 
 

median

3.0

2.8

 
 

range

0.20, 17.0

2.0, 12.0

 

Tumor stage, n (%),

  

0.545

 

T1

2 (7.14)

0 (0)

 
 

T2

26 (92.86)

14 (100)

 
 

unknown or other

2

1

 

Grade, n (%),

  

1.000

 

I

9 (81.82)

3 (75)

 
 

II

2 (18.18)

1 (25)

 
 

unknown or other

19

11

 

Lymphovascular invasion, n (%),

  

0.624

 

present

4 (21.05)

1 (8.33)

 
 

absent

15 (78.95)

11 (91.67)

 
 

unknown or other

11

3

 

ER status, n (%),

  

1.000

 

positive

28 (93.33)

14 (93.33)

 
 

negative

2 (6.67)

1 (6.67)

 

PR status, n (%),

  

0.695

 

positive

23 (76.67)

13 (86.67)

 
 

negative

7 (23.33)

2 (13.33)

 

HER2 status, n (%),

  

1.000

 

positive

1 (3.70)

1 (7.14)

 
 

negative

26 (96.30)

13 (92.86)

 
 

unknown or other

3

1

 

Lymph node status (%)

  

0.396

 

positive

6 (20)

1 (6.67)

 
 

negative

24 (80)

14 (93.33)

 

Primary treatment, n (%),

  

1.000

 

mastectomy

23 (76.67)

11 (73.33)

 
 

lumpectomy with RT

7 (23.33)

4 (26.67)

 

Follow up time, months

   
 

median

57

43

 
 

range

3, 139

12, 86

 

10-year disease-free survival

87.69%

75%

0.637

10-year overall survival rate

88.44%

100%

0.424

  1. ER estrogen receptor, PR progesterone receptor, RT radiotherapy.